Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Poster Session A

Vasculitis

Session: (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

0717: Mitochondria-mediated Platelet Activation in Polymyalgia Rheumatica

Sunday, November 12, 2023
9:00 AM – 11:00 AM PT
Location: Poster Hall
On Demand In Person

    Abstract Poster Presenter(s)

  • DM

    Despina Michailidou, MD (she/her/hers)

    University of Oklahoma and VA Medical Center
    Oklahoma, OK, United States

    Disclosure(s): Chemocentryx: Advisor or Review Panel Member (Terminated, September 29, 2021)

Despoina Michailidou1, Linda Johansson2, Jorge Armando Gonzalez-Chapa1, Ting Wang1, Junmei Chen3, José A. López3, Solbritt Rantapää-Dahlqvist4 and Christian Lood1, 1University of Washington, Seattle, WA, 2Umea University, Umea, Sweden, 3Bloodworks Research Institute, Seattle, WA, 4Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden

Background/Purpose: Platelets have been suggested to be involved in polymyalgia rheumatica (PMR) pathogenesis with elevated platelet activation observed in early stages of the disease. Upon platelet activation, mitochondria are expelled into the extracellular space. Extracellular mitochondria, due to their prokaryotic origin, are immunogenic and promote inflammation, as well as serve as a source of autoantigens leading to formation of anti-mitochondrial antibodies (AMAs). The purpose of this study was to explore whether patients with PMR have elevated plasma levels of thrombospondin-1 (TSP-1)—an alpha granule protein of human platelets, presence of the extracellular mitochondrial component N-formyl methionine peptide (fMET) in plasma, and autoantibodies directed towards specific mitochondrial antigens. We also sought to explore whether extracellular mitochondria could be mediators of platelet activation in patients with PMR.

Methods: Levels of TSP-1, fMET, and anti-mitofusin 1 IgG (anti-MFN1) were measured by ELISA in the plasma of healthy controls (HC, n=30) and PMR patients before (n=54) and after (n=60) treatment with glucocorticoids. Ultrapure mitochondria isolated from HepG2 cells were opsonized with patient (n=56) or healthy control (n=10) plasma and, upon washing, incubated with platelets isolated from a healthy donor in the presence of the fibrin polymerization inhibitor, GPRP. Mitochondria-mediated platelet activation was assessed by measurement of the platelet cell surface marker P-selectin via flow cytometry.

Results: Plasma levels of anti-MFN1 IgG, fMET, and TSP-1 were elevated in patients with PMR before glucocorticoid therapy compared to HC (p< 0.001, Table 1). Levels of anti-MFN1 IgG, fMET, and TSP-1 significantly decreased after treatment with glucocorticoids (p< 0.001, p< 0.001, and p=0.016 respectively, Table 2). Mitochondria opsonized with plasma factors from PMR patients showed markedly higher platelet activation than mitochondria opsonized with plasma factors from healthy individuals (p< 0.0001) (Figure 1A). Further, the extent of platelet activation (P-selectin level) by opsonized mitochondria correlated with plasma levels of TSP-1 in patients with PMR (r=0.48, p=0.0002, Figure 1B). TSP-1 levels were also associated with levels of immune complexes (IC) before glucocorticoid therapy. (r=0.32, p< 0.05).

Conclusion: Our results indicate increased platelet activation, the presence of mitochondrial damage-associated molecular patterns (DAMPs), and AMAs in the circulation of patients with PMR, associated with active disease. These results suggest a pathogenic involvement of mitochondrial antigens and autoantibodies in PMR. Blocking mitochondrial-mediated platelet activation may reduce inflammation in patients with PMR, with potential therapeutic implications.


Table 1. Median concentration of mitochondrial biomarkers and thrombospondin-1 (TSP-1) in patients with active PMR before glucocorticoid therapy compared to healthy controls.


Table 2. Median concentration of mitochondrial biomarkers and thrombospondin-1 (TSP-1) before and after glucocorticoid therapy in patients with PMR.


Figure 1. Mitochondrial-induced platelet activation in patients with PMR. A. Platelet rich plasma (PRP) from a healthy individual was exposed to mitochondria (mito) opsonized with plasma of patients with PMR (n=56) or HC (n=10. B. Plasma levels of TSP-1 were related to levels of mitochondrial-induced P-selectin in patients with PMR. Results are shown as the mean fluorescence intensity (MFI). Statistical analyses were done using the Mann-Whitney U-test and Spearman's correlation test. Each circle represents an individual sample, with the bar representing the median of the group.


D. Michailidou: Chemocentryx, 1; L. Johansson: None; J. Armando Gonzalez-Chapa: None; T. Wang: None; J. Chen: None; J. López: None; S. Rantapää-Dahlqvist: None; C. Lood: Amytryx, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, Citryll, 2, Eli Lilly, 5, Gilead, 5, Horizon Therapeutics, 5, Pfizer, 5, Redd Pharma, 5, 11.